Blair William & CO Ligand Pharmaceuticals Inc Transaction History

Blair William & CO

$34.8 Billion
Q2 2025

A detailed history of Blair William & CO transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Blair William & CO holds 7,701 shares of LGND stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,701

Previous 9,234 16.6%

Holding current value

$1.18 Million

Previous $970,000 9.79%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 24, 2025	SELL	$96.67 - $118.22 $148,195 - $181,231	-1,533 Reduced 16.6%	7,701 $875,000
Q1 2025 May 09, 2025	SELL	$105.14 - $122.23 $1,471 - $1,711	-14 Reduced 0.15%	9,234 $970,000
Q4 2024 Feb 12, 2025	BUY	$99.95 - $129.9 $3,298 - $4,286	33 Added 0.36%	9,248 $990,000
Q3 2024 Nov 12, 2024	BUY	$82.7 - $110.11 $6,616 - $8,808	80 Added 0.88%	9,215 $923,000
Q2 2024 Aug 12, 2024	SELL	$68.53 - $87.91 $685 - $879	-10 Reduced 0.11%	9,135 $769,000
Q1 2024 May 09, 2024	SELL	$68.64 - $89.2 $755 - $981	-11 Reduced 0.12%	9,145 $668,000
Q4 2023 Feb 12, 2024	SELL	$49.57 - $72.63 $48,330 - $70,814	-975 Reduced 9.62%	9,156 $653,000
Q2 2023 Aug 11, 2023	SELL	$69.53 - $79.33 $6,605 - $7,536	-95 Reduced 0.93%	10,131 $730,000
Q1 2023 May 12, 2023	SELL	$65.67 - $77.08 $328 - $385	-5 Reduced 0.05%	10,226 $752,000
Q3 2022 Nov 09, 2022	SELL	$0.01 - $107.56 $0 - $3,226	-30 Reduced 0.29%	10,231 $881,000
Q2 2022 Aug 10, 2022	SELL	$74.52 - $117.06 $152,169 - $239,036	-2,042 Reduced 16.6%	10,261 $915,000
Q1 2022 May 13, 2022	SELL	$94.99 - $151.56 $258,182 - $411,940	-2,718 Reduced 18.09%	12,303 $1.38 Million
Q4 2021 Feb 14, 2022	BUY	$127.69 - $165.85 $13,279 - $17,248	104 Added 0.7%	15,021 $2.32 Million
Q3 2021 Nov 12, 2021	BUY	$102.33 - $144.73 $29,368 - $41,537	287 Added 1.96%	14,917 $2.08 Million
Q2 2021 Aug 12, 2021	SELL	$113.03 - $155.64 $1.62 Million - $2.23 Million	-14,325 Reduced 49.47%	14,630 $1.92 Million
Q1 2021 May 13, 2021	SELL	$99.52 - $215.83 $337,273 - $731,447	-3,389 Reduced 10.48%	28,955 $4.41 Million
Q4 2020 Feb 09, 2021	BUY	$80.55 - $106.05 $641,741 - $844,900	7,967 Added 32.68%	32,344 $3.22 Million
Q3 2020 Nov 06, 2020	BUY	$89.56 - $126.72 $259,276 - $366,854	2,895 Added 13.48%	24,377 $2.32 Million
Q2 2020 Aug 12, 2020	SELL	$68.28 - $123.65 $68,143 - $123,402	-998 Reduced 4.44%	21,482 $2.4 Million
Q1 2020 May 11, 2020	SELL	$63.37 - $107.88 $402,082 - $684,498	-6,345 Reduced 22.01%	22,480 $1.64 Million
Q4 2019 Feb 13, 2020	BUY	$96.94 - $113.59 $25,786 - $30,214	266 Added 0.93%	28,825 $3.01 Million
Q3 2019 Nov 12, 2019	SELL	$86.25 - $120.16 $4.43 Million - $6.17 Million	-51,309 Reduced 64.24%	28,559 $2.84 Million
Q2 2019 Aug 13, 2019	SELL	$107.38 - $129.34 $1.15 Million - $1.38 Million	-10,670 Reduced 11.79%	79,868 $9.12 Million
Q1 2019 May 14, 2019	SELL	$105.93 - $142.47 $5.84 Million - $7.86 Million	-55,155 Reduced 37.86%	90,538 $11.4 Million
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $1.39 Million - $2.94 Million	10,801 Added 8.01%	145,693 $19.8 Million
Q3 2018 Nov 13, 2018	SELL	$211.18 - $274.49 $668,595 - $869,035	-3,166 Reduced 2.29%	134,892 $37 Million
Q2 2018 Aug 13, 2018	BUY	$150.77 - $207.98 $880,798 - $1.22 Million	5,842 Added 4.42%	138,058 $28.6 Million
Q1 2018 May 15, 2018	BUY	$138.63 - $182.62 $1.36 Million - $1.79 Million	9,812 Added 8.02%	132,216 $21.8 Million
Q4 2017 Feb 14, 2018	SELL	$128.36 - $147.04 $242,728 - $278,052	-1,891 Reduced 1.52%	122,404 $16.8 Million
Q3 2017 Nov 13, 2017	BUY	$120.91 - $137.94 $15 Million - $17.1 Million	124,295	124,295 $16.9 Million

Others Institutions Holding LGND

# of Institutions

293

Shares Held

19.4M

Call Options Held

Put Options Held

3.5K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.58B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account